Page 43 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zydus Cadila s ZyCov-D vaccine found to be safe and immunogenic

Zydus Cadila’s ZyCov-D vaccine found to be ‘safe and immunogenic’ December 24, 2020 Company wraps up Phase-I/II trials, eyes start of Phase-III Cadila Healthcare Ltd (Zydus Cadila) on Thursday informed that its plasmid DNA vaccine to prevent Covid-19, ZyCoV-D, was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials. The company has now sought approval to initiate Phase-III clinical trials in around 30,000 volunteers. The Phase-II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study, a statement said here.

Zydus cadilaPankajr patelZydus groupCadila healthcare ltd zydus onCentral drugs standard control organisationCadila healthcare ltdData safety monitoring boardஜய்துச் காடிலாஜய்துச் குழுகாடிலா சுகாதாரம் லிமிடெட் ஜய்துச் ஆன்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்காடிலா சுகாதாரம் லிமிடெட்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை

COVID: Zydus Cadila vaccine found safe in clinical trials

COVID: Zydus Cadila vaccine found safe in clinical trials
saharasamay.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saharasamay.com Daily Mail and Mail on Sunday newspapers.

Zydus cadilaPankajr patelZydus groupNational biopharma missionCentral drugs standard control organisationDepartment of biotechnologyData safety monitoring boardஜய்துச் காடிலாஜய்துச் குழுமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்துறை ஆஃப் உயிரி தொழில்நுட்பவியல்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை

Zydus Cadila seeks Phase 3 clinical trials approval for its Covid-19 vaccine

Zydus Cadila seeks Phase 3 clinical trials approval for its Covid-19 vaccine
hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.

Zydus cadilaPankajr patelZydus groupCentral drugs standard control organisationDrugs controller generalData safety monitoring boardNovel vaccineஜய்துச் காடிலாஜய்துச் குழுமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்மருந்துகள் கட்டுப்படுத்தி ஜநரல்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைநாவல் தடுப்பூசி

Zydus Cadila COVID-19 Vaccine Found Safe in Clinical Trials

Zydus Cadila COVID-19 Vaccine Found Safe in Clinical Trials by Colleen Fleiss on December 24, 2020 at 11:33 PM In the phase I and II clinical trials, Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D, was found to be safe, well tolerated and immunogenic. The company is now planning to initiate phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals. The phase II study of the vaccine ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study. The vaccine was found to be safe and immunogenic.

Zydus cadilaPankajr patelZydus groupNational biopharma missionEuropean union approves the usageEuropean unionEuropean medicines agencyCentral drugs standard control organisationDepartment of biotechnologyData safety monitoring boardMakes people motivatedMarket dashboard launchedUnion approvesPreferred greetingTrialsclinical trialsFutureclinical trials

Zydus Cadila Plans To Test Its COVID-19 Vaccine On 30,000 Volunteers In Late Stage Trial

Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials. December 25, 2020 / 08:21 PM IST Cadila Healthcare (Zydus Cadila) on December 24 said the company is planning to initiate Phase III clinical trial of its COVID-19 vaccine ZyCoV-D in around 30,000 volunteers upon receiving necessary approvals. The company said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials. In the Phase II study of the vaccine ZyCoV-D had been tested in over 1,000 healthy adult volunteers.

Pankaj patelZydus cadilaCentral drugs standard control organisationData safety monitoring boardBiosafety levelபங்கஜ் படேல்ஜய்துச் காடிலாமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை